ArticleNanomedicine (London, England)2020
Challenges to optimizing RNA nanostructures for large scale production and controlled therapeutic properties.
Article in Nanomedicine (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Nucleic acid nanotechnologies: transforming the future of precision medicine.Nanomedicine (London, England) · 2026Article
- RNA-DNA Fusomer Fibers With Customizable Physicochemical, Mechanical, and Biological Properties for Next-Generation Therapeutics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Advancements in RNA-based therapies from bench to bedside.npj drug discovery · 2026Review
- Nucleic Acid Nanoparticles Redefine Traditional Regulatory Terminology: The Blurred Line between Active Pharmaceutical Ingredients and Excipients.ACS nano medicine · 2025Article
- Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials.Molecular pharmaceutics · 2025Review
- Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Nanomaterial-Based Strategies to Combat Antibiotic Resistance: Mechanisms and Applications.Antibiotics (Basel, Switzerland) · 2025Review
- Recent Advances in Aptamers-Based Nanosystems for Diagnosis and Therapy of Cardiovascular Diseases: An Updated Review.International journal of nanomedicine · 2025Review
- RNA nanostructures for targeted drug delivery and imaging.RNA biology · 2024Review
- High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- A versatile, high-efficiency platform for CRISPR-based gene activation.Nature communications · 2023Article
- Light-Assisted Drying for the Thermal Stabilization of Nucleic Acid Nanoparticles and Other Biologics.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Expanding Structural Space for Immunomodulatory Nucleic Acid Nanoparticles (Nanps) via Spatial Arrangement of Their Therapeutic Moieties.Advanced functional materials · 2022Article
- The Application of Light-Assisted Drying to the Thermal Stabilization of Nucleic Acid Nanoparticles.Biopreservation and biobanking · 2022Article
- Article
- The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development.Advanced drug delivery reviews · 2022Review
- Drug delivery systems for RNA therapeutics.Nature reviews. Genetics · 2022Review
- Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.Advanced drug delivery reviews · 2022Review
Corrections and comments
- Erratum issuedErratum.2020
Authors and funding
4 authors.
Funding
Abstract
Nucleic acids have been utilized to construct an expansive collection of nanoarchitectures varying in design, physicochemical properties, cellular processing and biomedical applications. However, the broader therapeutic adaptation of nucleic acid nanoassemblies in general, and RNA-based nanoparticles in particular, have faced several challenges in moving towards (pre)clinical settings. For one, the large-batch synthesis of nucleic acids is still under development, with multi-stranded and chemically modified assemblies requiring greater production capacity while maintaining consistent medical-grade outputs. Furthermore, the unknown immunostimulation by these nanomaterials poses additional challenges, necessary to be overcome for optimizing future development of clinically approved RNA nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.